| Literature DB >> 35236745 |
Pauline E van Beek1, Monique Rijken2, Lisa Broeders3, Hendrik J Ter Horst4, Corine Koopman-Esseboom5, Ellen de Kort6, Céleste Laarman7, Susanne M Mulder-de Tollenaer8, Katerina Steiner9, Renate Mc Swarte10, Elke van Westering-Kroon11, S Guid Oei12,13, Aleid G Leemhuis14, Peter Andriessen15,16.
Abstract
OBJECTIVE: In 2010, the Dutch practice regarding initiation of active treatment in extremely preterm infants was lowered from 25 completed weeks' to 24 completed weeks' gestation. The nationwide Extremely Preterm Infants - Dutch Analysis on Follow-up Study was set up to provide up-to-date data on neurodevelopmental outcome at 2 years' corrected age (CA) after this guideline change. Design: National cohort study. PATIENTS: All live born infants between 240/7 weeks' and 266/7 weeks' gestational age who were 2 years' CA in 2018-2020. MAIN OUTCOME MEASURE: Impairment at 2 years' CA, based on cognitive score (Bayley-III-NL), neurological examination and neurosensory function.Entities:
Keywords: child health; epidemiology; infant development; intensive care units; neonatal; neonatology
Mesh:
Year: 2022 PMID: 35236745 PMCID: PMC9411912 DOI: 10.1136/archdischild-2021-323124
Source DB: PubMed Journal: Arch Dis Child Fetal Neonatal Ed ISSN: 1359-2998 Impact factor: 6.643
Baseline characteristics of all infants born at <27 weeks’ GA who reached 2 years’ CA in 2018–2020, and separately for infants born at 24 weeks’, 25 weeks’ and 26 weeks’ gestation
| Total | 24 weeks | 25 weeks | 26 weeks | P value | |
| Live born (N) | 991 | 271 | 297 | 423 | |
| Died before admission (N (% of live born)) | 100 (10.1) | 59 (21.8) | 24 (8.1) | 17 (4.0) | |
| Admitted (N (% of live born)) | 891 (89.9) | 212 (78.2) | 273 (91.9) | 406 (96.0) | |
| Died after admission (N (% of admitted)) | 240 (26.9) | 98 (46.2) | 68 (24.9) | 74 (18.2) | |
| Survived to 2 years’ CA (N (% of admitted)) | 651 (73.1) | 114 (53.7) | 205 (75.1) | 332 (81.8) | |
| Follow-up data available (N (% of survived)) | 554 (85.1) | 98 (86.0) | 178 (86.8) | 278 (83.7) | |
| Maternal age | 30.3 (5.2) | 30.7 (5.1) | 30.6 (5.2) | 30.1 (5.3) | 0.437 |
| Birth weight (g) | 820 (150) | 697 (99) | 799 (120) | 876 (154) | <0.001* |
| Sex (male) | 288 (52.0) | 46 (46.9) | 93 (52.2) | 149 (53.6) | 0.524 |
| SGA (<tenth percentile) | 99 (17.9) | 5 (5.1) | 27 (15.2) | 67 (24.1) | <0.001* |
| Caesarean section | 185 (33.4) | 14 (14.3) | 50 (28.1) | 121 (43.5) | <0.001* |
| Multiple birth | 154 (27.8) | 23 (23.5) | 51 (28.7) | 80 (28.8) | 0.573 |
| 5 min Apgar | 7(6, 8) | 7(5, 8) | 7(6, 8) | 7(6, 8) | <0.001* |
| Severe NEC | 63 (11.4) | 10 (10.2) | 21 (11.8) | 32 (11.5) | 0.919 |
| Severe brain injury | 85 (15.3) | 15 (15.3) | 27 (15.2) | 43 (15.5) | 0.996 |
| SES | 0.251 | ||||
|
| 141 (25.5) | 25 (25.5) | 46 (25.7) | 70 (25.3) | |
|
| 338 (61.1) | 53 (54.1) | 111 (62.4) | 174 (62.8) | |
|
| 74 (13.4) | 20 (20.4) | 21 (11.8) | 33 (11.9) | |
| Maternal education | 0.100 | ||||
|
| 63 (11.4) | 18 (18.4) | 14 (7.9) | 31 (11.2) | |
|
| 195 (35.2) | 37 (37.8) | 58 (32.6) | 100 (36.0) | |
|
| 208 (37.5) | 30 (30.6) | 78 (43.8) | 100 (36.0) | |
|
| 88 (15.9) | 13 (13.3) | 28 (15.7) | 47 (16.9) |
Birth weight is presented as mean (SD), Apgar score is presented as median (Q1, Q3), other variables are presented as N (%). SGA is defined as birth weight below the tenth percentile. A value of p<0.05 is considered statistically significant. *, significant at 0.05 level
CA, corrected age; GA, gestational age; NEC, necrotising enterocolitis; SES, socioeconomic status; SGA, small for gestational age.
Follow-up results of all 554 infants with follow-up data available born <27 weeks’ gestational age (GA) who reached 2 years’ corrected age (CA) in 2018–2020, separately for infants born at 24, 25 and 26 weeks’ gestation. All follow-up data are presented as N (%), mean (SD) or median (IQR). Impairment rates are presented as % (95% CI). The follow-up programme included a physical and neurological examination and assessment of mental and psychomotor development with the Dutch version of the Bayley Scales of Infant and Toddler Development (Bayley-III-NL, mean 100 (SD 15)). Parents are asked to fill out the Child Behavioral Checklist (CBCL) to rate internalising, externalising and total behaviour problems (mean 50 (SD 10), higher scores indicate more behavioural problems). Neurological examination was performed to determine cerebral palsy (CP), which was graded using the five levels defined in the Gross Motor Function Classification System (GMFCS), from 1 for minimal impairment to 5 for severe impairment with dependence on caretakers for most daily activities. A combination of medical history and results of the assessment was used to rate hearing and vision status. Outcome measures were compared between GA groups using a one-way analysis of variance or Mann-Whitney U-test for continuous variables, depending on distribution, and a χ2 test for categorical variables. A value of p<0.05 is considered statistically significant
| Total | 24 weeks | 25 weeks | 26 weeks | P value | |
| Follow-up data available | n=554 | n=98 | n=178 | n=278 | |
| Bayley-III-NL cognitive score, N (%) evaluated | 497 (89.7) | 87 (88.8) | 162 (91.0) | 248 (89.2) | |
| | 96 (14) | 94 (12) | 95 (15) | 97 (13) | 0.107 |
| | 96 (87–105) | 96 (87–101) | 96 (87–101) | 96 (88–105) | 0.135 |
| | 404 (81.3) | 70 (80.5) | 124 (76.5) | 210 (84.7) | 0.073 |
| | 77 (15.5) | 12 (13.8) | 30 (18.5) | 35 (14.1) | |
| | 16 (3.2) | 5 (5.7) | 8 (4.9) | 3 (1.2) | |
| Bayley-III-NL motor score, N (%) evaluated | 437 (78.9) | 80 (81.6) | 135 (75.8) | 222 (79.9) | |
| | 95 (14) | 92 (15) | 97 (14) | 95 (14) | 0.037* |
| | 95 (84–105) | 94 (83–101) | 98 (87–107) | 95 (87–106) | 0.053 |
| | 326 (74.6) | 51 (63.8) | 107 (79.3) | 168 (75.7) | 0.093 |
| | 94 (21.5) | 23 (28.8) | 25 (18.5) | 46 (20.7) | |
| | 17 (3.9) | 6 (7.5) | 3 (2.2) | 8 (3.6) | |
| Vision, N (%) evaluated | 533 (96.2) | 95 (96.9) | 170 (95.5) | 268 (96.4) | |
| | 450 (84.4) | 79 (83.2) | 140 (82.4) | 231 (86.1) | 0.175 |
| | 67 (12.6) | 16 (16.8) | 23 (13.5) | 28 (10.4) | |
| | 16 (3.0) | 0 (0.0) | 7 (4.1) | 9 (3.4) | |
| Hearing, N (%) evaluated | 529 (95.5) | 94 (95.9) | 171 (96.1) | 264 (95.0) | |
| | 508 (96.0) | 92 (97.9) | 162 (94.7) | 254 (96.2) | 0.356 |
| | 16 (3.0) | 2 (2.1) | 8 (4.5) | 6 (2.3) | |
| | 5 (0.9) | 0 (0.0) | 1 (0.6) | 4 (1.5) | |
| Neurological exam, N (%) evaluated | 530 (95.7) | 95 (96.9) | 170 (95.5) | 265 (95.3) | |
| | 440 (83.0) | 72 (75.8) | 142 (83.5) | 226 (85.3) | 0.116 |
| | 67 (12.6) | 17 (17.9) | 24 (14.1) | 26 (9.8) | |
| | 23 (4.3) | 6 (6.3) | 4 (2.4) | 13 (4.9) | |
| | |||||
| | 8 (34.8) | 2 (33.3) | 0 (0.0) | 6 (46.2) | |
| | 8 (34.8) | 2 (33.3) | 1 (25.0) | 5 (38.5) | |
| | 2 (8.7) | 2 (33.) | 0 (0.0) | 0 (0.0) | |
| | 1 (4.3) | 0 (0.0) | 0 (0.0) | 1 (7.7) | |
| | 4 (17.4) | 0 (0.0) | 3 (75.0) | 1 (7.7) | |
| | |||||
| | 7 (30.4) | 3 (50.0) | 0 (0.0) | 4 (30.8) | |
| | 5 (21.7) | 1 (16.7) | 1 (25.0) | 3 (23.1) | |
| | 3 (13.0) | 1 (16.7) | 0 (0.0) | 2 (15.4) | |
| | 2 (8.7) | 0 (0.0) | 0 (0.0) | 2 (15.4) | |
| | 6 (26.1) | 1 (16.7) | 3 (75.0) | 2 (15.4) | |
| CBCL Total T-score, N (%) evaluated | 397 (71.7) | 70 (71.4) | 130 (73.0) | 197 (70.9) | |
| | 48 (10) | 49 (9) | 47 (10) | 48 (10) | 0.717 |
| | 47 (40–55) | 47 (43–54) | 47 (39–55) | 48 (40–56) | 0.677 |
| | 358 (90.2) | 64 (91.4) | 118 (90.8) | 176 (89.3) | 0.605 |
| | 34 (8.6) | 4 (5.7) | 11 (8.5) | 19 (9.6) | |
| | 5 (1.3) | 2 (2.9) | 1 (0.8) | 2 (1.0) | |
| CBCL Internalising T-score, N (%) evaluated | 398 (71.8) | 71 (72.4) | 130 (73.0) | 197 (70.9) | |
| | 47 (11) | 48 (9) | 46 (11) | 47 (11) | 0.763 |
| | 45 (41–55) | 47 (41–55) | 45 (37–55) | 45 (37–55) | 0.712 |
| | 359 (90.2) | 66 (93.0) | 118 (90.8) | 175 (88.8) | 0.755 |
| | 33 (8.3) | 5 (7.0) | 10 (7.7) | 18 (9.1) | |
| | 6 (1.5) | 0 (0.0) | 2 (1.5) | 4 (2.0) | |
| CBCL Externalising T-score, N (%) evaluated | 398 (71.8) | 71 (72.4) | 130 (78.0) | 197 (70.9) | |
| | 49 (10) | 50 (9) | 49 (10) | 49 (10) | 0.925 |
| | 50 (42–56) | 48 (44–56) | 48 (42–56) | 50 (42–56) | 0.869 |
| | 356 (89.4) | 66 (93.0) | 114 (87.7) | 176 (89.3) | 0.828 |
| | 36 (9.0) | 4 (5.6) | 14 (10.8) | 18 (9.1) | |
| | 6 (1.5) | 1 (1.4) | 2 (1.5) | 3 (1.5) | |
| Impairment, including Bayley-III-NL cognitive score, vision, hearing and neurological exam, N (%) evaluated | 554 (100) | 98 (100) | 178 (100) | 278 (100) | |
| | 61.9% (58–66) | 55.1% (45–65) | 56.7% (49–64) | 67.6% (62–73) | 0.072 |
| | 29.1% (25–33) | 35.7% (27–46) | 33.7% (27–41) | 23.8% (19–29) | |
| | 9.0% (7–12) | 9.2% (5–17) | 9.6% (6–15) | 8.6% (6–13) | |
| Impairment, including the above and also Bayley-III-NL motor score, N (%) evaluated | 464 (83.8) | 83 (84.7) | 146 (82.0) | 235 (84.5) | |
| | 53.0% (48–58) | 43.4% (33–54) | 51.4% (43–59) | 57.4% (51–64) | 0.225 |
| | 34.3% (30–39) | 43.4% (33–54) | 35.6% (28–44) | 30.2% (25–36) | |
| | 12.7% (10–16) | 13.2% (8–22) | 13.0% (8–19) | 12.3% (9–17) | |
| Impairment, including the above and also CBCL T-scores, N (%) evaluated | 364 (65.7) | 69 (70.4) | 118 (66.3) | 177 (63.7) | |
| | 45.6% (41–51) | 40.6% (30–52) | 40.7% (32–50) | 50.9% (44–58) | 0.249 |
| | 35.7% (31–41) | 42.0% (31–54) | 40.7% (32–50) | 29.9% (24–37) | |
| | 18.7% (15–23) | 17.4% (10–28) | 18.6% (13–27) | 19.2% (14–26) |
*Pairwise analysis showed a significant difference in Bayley-III-NL motor score between 24 weeks’ and 25 weeks’ gestation (p=0.014).
Logistic regression to evaluate the effect of different perinatal factors on NDI
| NDI | |
| OR (95% CI) | |
| GA (days) | 0.98 (0.93 to 1.03) |
| Female | 0.95 (0.53 to 1.79) |
| SGA | 1.47 (0.66 to 3.07) |
| NEC | 1.32 (0.51 to 3.02) |
| Severe brain injury | 2.63 (1.32 to 5.05)* |
| Low maternal education | 2.58 (1.26 to 5.03)* |
Numbers are presented as OR with 95% CI. Being female was compared with the reference category of being male, low maternal education was compared with a reference category of intermediate–high education. *significant at 0.05 level.
GA, gestational age; NDI, neurodevelopmental impairment; NEC, necrotising enterocolitis; SGA, small for gestational age.
Figure 1(A) Imputed overall neurodevelopmental outcome, classified as no, mild or moderate-to-severe impairment (ie, NDI), using defined categories of cognitive development, neurological examination and neurosensory function for different GA groups, using all live-born infants as the denominator. (B) Imputed overall neurodevelopmental outcome, classified as no, mild or moderate-to-severe impairment (ie, NDI), using defined categories of cognitive development, neurological examination and neurosensory function, using all NICU-admitted infants as the denominator. GA, gestational age; NDI, neurodevelopmental impairment; NICU, neonatal intensive care unit. Figures might not add up to 100% due to rounding.